Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally.
Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.
The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.
It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.
The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | 1.12 Decreased by -14.50% | 1.08 Increased by +3.70% |
| May 3, 24 | 1.22 Increased by +12.96% | 0.97 Increased by +25.77% |
| Feb 15, 24 | 0.88 Increased by +8.64% | 0.83 Increased by +6.02% |
| Nov 2, 23 | 0.87 Decreased by -34.09% | 1.06 Decreased by -17.92% |
| Aug 8, 23 | 1.31 Increased by +4.80% | 1.01 Increased by +29.70% |
| May 4, 23 | 1.08 Decreased by -34.55% | 1.16 Decreased by -6.90% |
| Feb 16, 23 | 0.81 Decreased by -40.88% | 0.90 Decreased by -10.00% |
| Nov 3, 22 | 1.32 Decreased by -20.96% | 1.09 Increased by +21.10% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.58 B Increased by +4.15% | 359.00 M Increased by +518.97% | Increased by +22.69% Increased by +494.32% |
| Jun 30, 24 | 1.61 B Decreased by -0.06% | 195.00 M Decreased by -19.42% | Increased by +12.13% Decreased by -19.37% |
| Mar 31, 24 | 1.62 B Increased by +5.46% | 201.00 M Increased by +13.56% | Increased by +12.39% Increased by +7.68% |
| Dec 31, 23 | 1.60 B Increased by +7.61% | 546.00 M Increased by +405.56% | Increased by +34.17% Increased by +369.81% |
| Sep 30, 23 | 1.52 B Decreased by -1.17% | 58.00 M Decreased by -74.45% | Increased by +3.82% Decreased by -74.15% |
| Jun 30, 23 | 1.61 B Increased by +1.45% | 242.00 M Increased by +3.42% | Increased by +15.05% Increased by +1.94% |
| Mar 31, 23 | 1.54 B Decreased by -1.85% | 177.00 M Decreased by -49.14% | Increased by +11.51% Decreased by -48.18% |
| Dec 31, 22 | 1.49 B Decreased by -7.42% | 108.00 M Decreased by -46.53% | Increased by +7.27% Decreased by -42.25% |